Full-Time
Strategic Account Manager
Health Systems, Screening, North Central
Posted on 9/4/2025
Guardant Health
1,001-5,000 employees
FDA-approved blood-based cancer diagnostics provider
No salary listed
Dallas, TX, USA
Hybrid
Location specified as North Central, US; remote option indicated but travel up to 50% within territory; title mentions North Central US. No in-person requirement beyond travel.
 Sales & Account Management (5) |
|---|
| , , , , |
- 5+ years in strategic account management within diagnostics, vaccines, or biopharma, with a proven track record of exceeding sales goals.
- Established relationships with key decision-makers in large Health Systems and IDNs (preferred).
- Demonstrated success launching new products, including system-level approval, integration, and pull-through.
- Experience delivering measurable revenue growth and account penetration in competitive markets.
- Deep understanding of healthcare ecosystems and influencing system strategy.
- Skilled in consultative, executive-level selling, negotiation, and objection handling.
- Proven ability to influence strategic decisions and lead complex projects without direct authority.
- Strong cross-functional collaboration skills and ability to manage multiple stakeholders.
- Highly organized, proactive communicator with advanced project management capabilities.
- Proficiency with Microsoft Office (Excel, PowerPoint) and CRM tools (Salesforce.com preferred).
- Bachelor’s degree in Life Sciences, Biology, Business, Marketing, or related field (preferred).
- Develop and execute territory business plans aligned with brand strategy, with independent authority to tailor approaches to individual accounts.
- Build and maintain strong relationships with C-suite executives, clinical leaders, and administrative stakeholders in target organizations.
- Lead cross-functional initiatives to ensure smooth product launch, integration, and pull-through in assigned accounts.
- Identify market opportunities, monitor competitive activity, and provide actionable insights to leadership.
- Develop strategic partnerships to maximize Shield adoption and long-term account retention.
- Achieve or exceed assigned territory sales quota and adoption targets for Shield across designated IDNs and Health Systems.
- Serve as a mentor and resource for new account managers and sales specialists, supporting onboarding and best-practice sharing.
- Work collaboratively with cross-functional team members including medical affairs, sales, managed care and market access.
- Represent Guardant Health’s mission, culture, and values to internal and external stakeholders.
- Adhere to all Compliance, Regulatory, and Quality Management System (QMS) policies.
- Travel up to 50% within territory, with occasional regional or national meetings.
- Meet all applicable customer access requirements.
- Established relationships with key decision-makers in large Health Systems and IDNs (preferred).
- Experience delivering measurable revenue growth and account penetration in competitive markets.
- Bachelor’s degree in Life Sciences, Biology, Business, Marketing, or related field (preferred).
Guardant Health develops blood-based cancer diagnostics and sells tests to healthcare providers and research institutions. Its flagship product, Guardant360, uses a liquid biopsy to analyze tumor DNA circulating in a patient’s blood to detect mutations and guide treatment decisions for advanced cancer. The company is expanding into early detection and recurrence monitoring, with tests designed to be non-invasive and data-rich for cancer management. Compared with competitors, Guardant Health emphasizes a widely adopted, FDA-approved liquid biopsy platform with broad cancer-type coverage and a focus on providing actionable genomic insights to clinicians. Its goal is to improve cancer outcomes by enabling non-invasive, data-driven decision making across stages of disease and over time.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Simplify's Take
What believers are saying
- Q1 2026 revenue surged 48% to $302M, raising FY guidance to $1.30-1.32B.
- Nuvalent collaboration on April 30, 2026, expands CDx for NSCLC therapies.
- Verana Health partnership on March 24, 2026, accelerates biomarker therapy development.
What critics are saying
- Illumina Grail Galleri erodes Shield share in $18B screening market within 12 months.
- FoundationOne Liquid CDx captures Guardant360 volume via Roche sales force.
- $112M Q1 2026 net loss exhausts $1.2B cash before 2027 breakeven.
What makes Guardant Health unique
- Guardant360 CDx holds 26 FDA companion diagnostic approvals across tumor types.
- Guardant Infinity platform combines tissue and liquid biopsies for biopharma trials.
- Shield test targets $18B colorectal screening with Quest Diagnostics partnership.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -1%Guardant Health, Nuvalent ink oncology companion diagnostic development pact. NEW YORK - Guardant Health announced on Thursday that it has entered into a multi-year strategic collaboration with biopharma company Nuvalent to develop and potentially commercialize companion diagnostics for oncology. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month
Inside Quest Diagnostics' daytime kidney care lab strategy. In this exclusive interview, Quest Diagnostics' Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann. April 6, 2026 Ines Dahne-Steuber is Vice President and General Manager of Kidney Care at Quest Diagnostics. Most recently, Ines served as Chief Operating Officer for Guardant Health. Prior to that, she served as SVP of Operational Excellence and President of Spectra Labs for Fresenius Medical Care. Ines previously worked at Quest Diagnostics from 2005-2015 in several roles, including as VP of Process Excellence and Healthcare IT. She earned bachelor's and master's degrees in Modern Chinese and Romance Studies from Humboldt-University in Berlin, Germany. MLO: dialysis patients have unique and often complex testing needs. How has Quest Diagnostics adapted its daytime operations to better support this population, and what operational changes have made the biggest impact on patient care? Dahne-Steuber: Quest operates major clinical laboratories all over the U.S., so Mlo Online is well positioned to serve patients in their local communities, wherever they live. To best accommodate the unique needs of dialysis patients, Mlo Online has chosen to perform testing at all 16 participating Quest Diagnostics labs during daytime operations so that staff can give these samples special attention without impacting other patient testing commitments. Dialysis patients have unique physiologies, which lead to more clotted samples. These clots can impact testing performance and need to be managed diligently.
Guardant Health (GH) and Verana Health announces new partnership. Noor Ul Ain Rehman Guardant Health, Inc. (NASDAQ:GH) is one of the best high growth healthcare stocks to buy now. Guardant Health, Inc. (NASDAQ:GH) and Verana Health announced on March 24 a new partnership aimed at allowing biopharmaceutical researchers to access the combined resources of Guardant's clinicogenomic testing data and Verana's regulatory-grade, therapeutic-specific EHR curated datasets to expedite the development of new therapies and enhance ongoing patient care. Management stated that the collaboration provides extensive datasets that would allow research scientists to easily understand and validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes. Craig Eagle, MD, Guardant Health, Inc. (NASDAQ:GH) chief medical officer, stated that the real-world data partnership with Verana marks a considerable milestone in the company's mission to advance novel therapies, in particular cancer, with data. He added that allowing "biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data" would accelerate the discovery of new biomarker-based therapies for patients, helping make the drug development process more economical. Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in treating cancer through vast data sets, proprietary blood-based tests, and advanced analytics. The company's solutions include recurrence detection, early detection, and treatment selection. While Need2learnchinese acknowledge the potential of GH as an investment, Need2learnchinese believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see its free report on the best short-term AI stock.
Guardant Health wins at Healthcare Asia Medtech Awards 2026. The ShieldTM Multi-cancer Detection (MCD) test offers screening for 10 types of cancers with just a blood draw. Guardant Health Pte Ltd won Oncology Product Innovation of the Year in the Healthcare Asia Medtech Awards 2026 for the Shield MCD test. The Shield MCD test detects multiple cancer types from DNA shed in the blood. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types, including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer in individuals aged 45 years or older without a known diagnosis of cancer, and it is not indicated for use in pregnant women. In the United States, the Shield MCD test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Data from the 2025 American Association for Cancer Research annual meeting showed that the Shield MCD test achieved 99% overall specificity and 74% sensitivity across six aggressive cancers, including esophageal-gastric, hepatocellular, lung, ovarian, and pancreatic. The test also predicted cancer signals of origin with 93% accuracy. The FDA Breakthrough Device designation referenced eight cancer types - bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancer - in individuals aged 45 or older who are at typical average risk for cancer, as defined by the agency at the time of designation. This designation does not imply FDA approval, clearance, or endorsement of the device's safety or effectiveness. Join Healthcare Asia Magazine community The Healthcare Asia Medtech Awards honours the most exemplary medtech companies across Asia. It serves as a platform for organisations to showcase their pioneering medical devices, life-saving software, or top-notch healthcare solutions, amongst other innovations. Laboratory and test information: The Shield MCD is a laboratory-developed test that was developed and whose performance characteristics were determined by Guardant Health, Inc. This test may be used for clinical purposes and should not be regarded as investigational or for research only. Guardant Health's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing and accredited by the College of American Pathologists (CAP). This test is not part of the Shield IVD and has not been cleared or approved by the FDA. For Export Use Only. Not for sale or use in the United States. The Healthcare Asia Medtech Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be acclaimed for your organisation's initiatives and contribution to enhancing the industry's overall performance, please contact Julie Anne Nuñez-Difuntorum at [email protected].
Guardant Health has received a Moderate Buy consensus from 23 analysts, with an average price target of $122.57, implying 43% upside from its recent share price of $85.49. Piper Sandler maintained a Buy rating with a $130 target following recent company presentations. The precision oncology company reported fourth-quarter 2025 revenue of $281.3 million, up 39% year over year, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million. Guardant expects total 2026 revenue growth of 27% to 30%. At recent healthcare conferences, management highlighted its Quest Diagnostics partnership for Shield and noted that 90% of Shield users had not been screened in the prior five years, suggesting the product can expand rather than compete within the existing screening market.